Sunitinib May Be Acceptable First Line Treatment for Metastatic Renal Cell Carcinoma

Share this content:
Sunitinib represents an acceptable option in first line treatment for mPRCC.
Sunitinib represents an acceptable option in first line treatment for mPRCC.

Sunitinib represents an acceptable option in first line treatment for metastatic papillary renal cell carcinoma (mPRCC), a recent study published early online in the journal Annals of Oncology has shown.

Because there is currently no standard first line treatment for mPRCC, researchers designed a prospective phase II study to evaluate sunitinib in first line treatment of patients with mPRCC.

Researchers enrolled 15 patients with type 1 and 46 patients with type 2 mPRCC. Of those, 12 were in the favorable risk group, 33 were in the intermediate risk group, 9 were in the poor risk group, and 7 were undetermined.

Results showed that at a median follow-up time of 51.4 months, 13% (95% CI: 0.1 - 30.5) of those with type mPRCC achieved a partial response, 67% had stable disease with 33% of patients having stable disease at least 12 weeks.

For those with type 2, 11% (95% CI: 1.9 - 20.3) achieved a partial response, 54% had stable disease with 22% of patients having stable disease at least 12 weeks.

RELATED: Urine Test for Kidney Cancer Showing Promise

Median progression-free survival was 6.6 months (95% CI: 2.8 - 14.8) and 5.5 months (95% CI: 3.8 - 7.1) for type 1 and type 2, respectively. Median overall survival was 17.8 months (95% CI: 5.7 - 26.1) for type 1 and 12.4 months (95% CI: 8.2 - 14.3).

The findings suggest that sunitinib shows activity in both types of mPRCC, but lower activity than in clear cell metastatic renal cell carcinoma (mRCC).

Reference

  1. Ravaud A, Oudard S, De Fromont M, et al. First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG). Ann Oncol. 2015. doi: 10.1093/annonc/mdv149.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters